Diagnosis, Risk-Stratification, Management Updates in Myelodysplastic Syndromes
An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.
Myelodysplastic Syndromes
MYELODYSPLASTIC SYNDROMES
FEATURE
LATEST NEWS
Imetelstat May Benefit Patients With Lower Risk MDS
Researchers sought to determine whether imetelstat would have efficacy in patients with lower risk MDS that is relapsed/refractory to erythropoiesis stimulating agents.
Substantial Proportion of Patients With MDS or AML Not Considered for HCT
Researchers sought to determine the proportion of potentially eligible patients with high-risk MDS or AML who are considered for HCT.
Luspatercept Gets Priority Review for First-Line Tx of Anemia in Lower-Risk MDS
The FDA has assigned a Prescription Drug User Fee Act goal date of August 28, 2023.
IPSS-M Shows Strong Predictive Power in Myelodysplastic Syndrome
Researchers sought to determine whether the Molecular IPSS system would improve prognostic classification for patients with MDS.
Increased Infection, Reduced Hematopoietic Stem Cell Transplantation Rates Seen in TP53-Mutated MDS/AML
Researchers sought to determine the impact of TP53 mutations on infection and HCT rates in patients with MDS/AML.
Magrolimab Plus Azacitidine Well Tolerated With Promising Efficacy in Higher-Risk Myelodysplastic Syndrome
Researchers sought to determine whether magrolimab combined with azacitidine would be an effective treatment for patients with high-risk MDS.
Treatment Selection and Symptom Management After MDS/MDN Diagnosis
A review of MDS/MDN, including new WHO guidelines and collaborative strategies for managing the care of patients with lower-risk MDS.
Frailty Predicts Increased Cost of Care in Myelodysplastic Syndromes
Researchers sought to determine whether a higher frailty score would be linked with cost of care in patients with MDS.
Invasive Aspergillosis Linked With Risk of Death in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Researchers sought to determine whether invasive aspergillosis had a link with risk of death in older patients with AML or MDS.
Early Active Treatment Strategies Improve Outcomes in Newly Diagnosed High-Risk Myelodysplastic Syndrome
Researchers sought to determine whether early treatment strategies would be beneficial in patients with newly diagnosed, high-risk MDS.
Blood Supply Shortages Impact Some Patients With Myelodysplastic Syndromes
Researchers sought to address the reported blood shortages for patients with MDS in Europe.
Low-Dose Lenalidomide Confirmed to Reduce Time to Transfusion Dependence in Lower-Risk MDS
Researchers sought to determine whether low-dose lenalidomide would prolong time to transfusion dependence among patients with low-risk MDS.
Associations of Mutations in Spliceosome Genes With Ring Sideroblasts Verified in Myelodysplastic Syndromes
Researchers sought to verify the association of mutations in the splicing pathway gene SF3B1 with low bone marrow blast counts and increased ring sideroblasts in MDS.
Biological and Survival Outcomes of MDS Different Between Sexes
Researchers sought to determine sex differences in patients with myelodysplastic syndrome.
Ongoing Study Evaluates Diagnosis of Myelodysplastic Syndrome With Peripheral Blood Samples
A study is being conducted to evaluate an approach to diagnosis of myelodysplastic syndrome using samples obtained from peripheral blood.
Clinical Outcomes Similar With 5- or 7-Day Azacitidine in Lower-Risk Myelodysplastic Syndrome
Researchers sought to determine whether there would be a difference in outcomes for patients with lower-risk MDS with either a 5- or 7-day dosing schedule of azacitidine.
RUNX1 Deficiency, SRSF2 Mutation Induce Hematopoietic Defects in MDS
Researchers sought to determine whether RUNX1 deficiency would impact multilineage hematopoietic defects in patients with MDS.
Immune Dysregulation and the Role of Immunotherapy in Myelodysplastic Syndrome
The authors of this study used the “Yin-Yang theory” to characterize the role that immune dysregulation plays in the pathogenesis of MDS.
Prolonged Isolated Thrombocytopenia After HSCT Has Prognostic Value in Myelodysplastic Syndromes
Researchers sought to determine whether prolonged isolated thrombocytopenia impacted survival in patients with MDS.
Differences in Cytopenia in MDS May Be Related to Genetic Mutations
Researchers sought to determine whether there were differences in cytopenia and other factors in patients with MDS or MPN.
Online Educational Program Improves Patient Understanding in Myelodysplastic Syndromes
Researchers sought to determine whether an online educational program regarding myelodysplastic syndromes would provide benefits to learners’ understanding of MDS.
Fibrinogen May Be Associated With Poor Prognosis in Myelodysplastic Syndrome
Researchers sought to determine the role of fibrinogen levels in patients with myelodysplastic syndrome.
Post-Transplantation Prognostic Model Developed for Myelodysplastic Syndromes
Researchers sought to develop a clinical risk model for predicting survival outcomes with allogeneic transplantation in patients with MDS.
TP53 Mutations Predict Poor Outcomes in Patients With MDS or AML With Complex Karyotype
Researchers sought to determine whether TP53 mutations would be linked with more aggressive disease in patients with MDS or AML.
Pretreatment Peripheral Blood Inflammatory Indices May Have Prognostic Value in Myelodysplastic Syndrome
Researchers sought to determine whether elevated platelet-to-lymphocyte ratio and plasma C-reactive protein level would help predict prognosis for patients with MDS.
Longer Azacitidine Schedule Delayed Transformation to Leukemia in Patients With MDS
A head-to-head comparison of 7-day and 5-day treatment schedule of azacitidine in patients with higher risk myelodysplastic syndromes revealed trends in overall survival and time to transformation to leukemia.
Optimizing Outcomes in Low-Risk Myelodysplastic Syndromes
Diagnosis, goals of care, and treatment options for MDS are discussed in a presentation at 2022 ONA Summit.
TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes: Is Transplant Effective?
Researchers are trying to determine the optimal treatment strategy among patients with TP53-mutated AML or MDS.
Lower Apolipoprotein A1 Prognostic for Worse Outcomes in Myelodysplastic Syndromes
Researchers sought to determine whether levels of apolipoprotein A1 would be prognostic for disease outcomes in patients with MDS.
Features and Outcomes in Myelodysplastic Syndrome, Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis
Researchers sought to characterize features and outcomes specific to patients with MDS and MPNs with ring sideroblasts and thrombocytosis.
Features Related to Failure to Reach Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes
Researchers sought to identify features related to failure to reach allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes.
CADM1 Tumor Suppressor Gene Identified as Candidate Gene in Myelodysplastic Syndromes With Del(11q)
Researchers sought to determine whether the tumor suppressor gene CADM1 would be a factor influencing MDS with del(11q).
Tamibarotene Gets Orphan Drug Status for Myelodysplastic Syndrome
Tamibarotene is an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist.
Features and Treatment for Iron Overload in Patients With Myelodysplastic Syndrome
Researchers sought to define the features and treatments for iron overload in patients with transfusion-dependent myelodysplastic syndrome.
Geno-Clinical Decision Model Accurately Predicts Diagnosis of Myelodysplastic Syndrome
Researchers sought to determine whether a machine learning-based model would be able to accurately predict the diagnoses of myeloid malignancies.
Nonablative Chemotherapy Paired With Novel T-Cell Therapy Appears Safe and Effective in Older Patients With AML and MDS
Researchers sought to determine whether nonablative chemotherapy followed by HLA-mismatched allogeneic T-cell infusion would be safe and effective in older patients with AML or MDS.
PARP1 Represents a Promising Therapeutic Target in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Researchers sought to determine the role of PARP1 in the physiological and pathological effects in MDS and AML.
How Can Lifestyle Factors Affect Myeloproliferative Neoplasms?
As myeloproliferative neoplasms (MPN) are a particularly rare form of blood cancer without a clear cause, it may be difficult to understand how lifestyle factors can affect both MPN risk and symptom burden. What has research suggested about the ways certain lifestyle factors affect MPNs?
Features of TERT Rare Variants in Patients With Myelodysplastic Syndrome
Researchers sought to determine the effects of TERT rare variants in patients with myelodysplastic syndrome.
Predicting Post-Transplant Disease Progression in Myelodysplastic Syndrome
Researchers sought to determine whether detecting MRD with mutational analysis and FCM may aid in predicting disease progression following myeloablative allo-HSCT in patients with MDS.
Allogeneic Hematopoietic Stem Cell Transplantation Negates Poor Outcomes in Myelodysplastic Syndrome With Myelofibrosis
Researchers sought to determine whether allo-HSCT would negate poorer outcomes in patients with MDS who have myelofibrosis.
Safety of a Bispecific Antibody in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Researchers sought to determine whether APVO436 would have a favorable safety profile in treating patients with relapsed/refractory AML or MDS.
Role of Bone Marrow Microenvironment in Myelodysplastic Syndromes
Researchers sought to determine how the bone marrow microenvironment contributes to the etiology of myelodysplastic syndrome.
Current and Future Perspectives of Precision Medicine in Patients With Myelodysplastic Syndromes
Researchers sought to review the current understanding and available treatments of myelodysplastic syndromes as well as future perspectives.
Myeloproliferative Neoplasms: How Do MPNs Affect Quality of Life?
As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?
Possible Response Biomarkers Identified in Non-Del(5q) Lower-Risk Myelodysplastic Syndrome
Researchers seek to identify biomarkers that may be predictive of erythroid response in patients with lower-risk myelodysplastic syndromes without a chromosome 5q deletion.
Differences in Myelodysplastic Syndromes Treatment Guidelines Do Not Account for Variable Treatment Decisions
Researchers sought to determine whether differences in treatment guidelines for MDS would account for nonadherence to expert guidance.
Leukemic Transformation in Patients With Myelodysplastic Syndrome With Myelofibrosis
Researchers sought to identify inflammation-related genes that may be associated with leukemic transformation in patients with MDS with myelofibrosis.
EU Approves Luspatercept for Select Patients With Myelodysplastic Syndrome or Beta-Thalassemia
Researchers sought to review the EU’s marketing authorization for luspatercept to treat select patients with MDS or transfusion-dependent beta thalassemia.
IRF4 Gene Expression Associated With Development of Acute Myeloid Leukemia, Myelodysplastic Syndrome
Researchers sought to determine whether IRF4 expression is associated with an increased susceptibility to de novo AML and myelodysplastic syndrome.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Myelodysplastic Syndromes
Loading... 
Loading...